Artiva Shares Jump 30% After Upsized $167 Million US IPO
The company focuses on developing natural killer cell-based therapies for patients suffering from devastating autoimmune diseases and cancers.
Photographer: Pablo Blazquez Dominguez/Getty ImagesThis article is for subscribers only.
Artiva Biotherapeutics Inc. shares pared initial gains to end flat in the company’s trading debut after raising $167 million in an expanded initial public offering.
Shares of the clinical stage biotechnology company, backed by South Korea’s Green Cross Corp., traded as high as $16 each before retreating to their $12 IPO price on Friday in New York. Artiva sold almost 14 million shares Thursday, after marketing 8.7 million of them for $14 to $16 each.